Glecirasib

Glecirasib
Clinical data
Drug class	KRAS G12C inhibitor
Legal status
Legal status	Rx in China;
Identifiers
	IUPAC name 7-(2-amino-3,4,5,6-tetrafluorophenyl)-6-chloro-1-(4-methyl-2-propan-2-yl-3-pyridinyl)-2-oxo-4-(4-prop-2-enoylpiperazin-1-yl)-1,8-naphthyridine-3-carbonitrile;
CAS Number	2657613-87-9;
PubChem CID	157827766;
Chemical and physical data
Formula	C31H26ClF4N7O2
Molar mass	640.04 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=C(C2=O)C#N)N4CCN(CC4)C(=O)C=C)Cl)C5=C(C(=C(C(=C5F)F)F)F)N;
	InChI InChI=1S/C31H26ClF4N7O2/c1-5-19(44)41-8-10-42(11-9-41)29-16-12-18(32)27(20-21(33)22(34)23(35)24(36)25(20)38)40-30(16)43(31(45)17(29)13-37)28-15(4)6-7-39-26(28)14(2)3/h5-7,12,14H,1,8-11,38H2,2-4H3; Key:QRRJEUIQLZNPIO-UHFFFAOYSA-N;

Drug classKRAS G12C inhibitor

Legal status

Rx in China

CAS Number

2657613-87-9

PubChem CID

157827766

Glecirasib (JAB-21822) is a pharmaceutical drug used for cancer treatment. It is a selective inhibitor of the G12C mutant version of the enzyme KRAS. It is used as a combination treatment alongside other selective enzyme inhibitors.^[1]^[2]^[3]^[4]

[1]

[2]

[3]

[4]

Glecirasib

Related Articles

Timelines

Top Qs

Fact Checks